A New Current to The Armamentarium: Is the CHA2DS2-Vasc-HS Score Predictive of Low Left Internal Mammary Artery (LIMA) Flow in Patients Underwent Coronary Bypass Surgery?
LIMA flow and CHA2DS2-Vasc-HS score
Keywords:CHA2DS2-Vasc-HS score, LIMA flow, CAD
Introduction: Left internal mammary artery (LIMA) grafts should be used in patients undergoing CABG. No other procedure results in patency equivalent to that of the left anterior descending coronary artery (LAD)–LIMA bypass graft. The CHA2DS2-Vasc-HS scoring system can be used to successfully predict CAD severity in stable CAD patients. We aimed to investigate the relationship between LIMA flow and the CHA2DS2-Vasc-HS score.
Methods: A total of 684 patients, who underwent CABG surgery, were included in this study. Previous history of bypass surgery, emergency operations, patients with Leriche syndrome and patients with severe obstructive pulmonary and subclavian artery disease were excluded from our study. Patients with a LIMA flow that was suitable for bypass grafting, as determined during the intraoperative evaluation, were included in the low LIMA flow group, and the CHA2DS2-Vasc-HS score was calculated for all patients.
Results: Patients in the low LIMA flow group (Group 1) were older. The CHA2DS2-Vasc-HS score (P < 0.001), presence of mild or moderate COPD (P = 0.022), number of severely diseased vessels (P = 0.036), and BMI (P < 0.001) were independent predictors of poor LIMA flow. The cutoff value of the CHA2DS2-VASc-HS score for the prediction of poor LIMA flow was >5.5, with a sensitivity of 92.9% and specificity of 83.4% (AUC: 0.938, 95% Cl: 0.906 – 0.970, P < 0.001).
Conclusion: A preoperative high CHA2DS2-Vasc-HS score can be used to predict low intraoperative LIMA flow. The CHA2DS2-Vasc-HS score is an easy-to-use and reliable estimation method and can be used as an additional preoperative of LIMA flow in patients undergoing CABG due to severe CAD.
Bahar L, Tüysüz ME. 2020. The Relationof Left Internal Mammary Artery Atherosclerosis With Urotensin II. Bratislava Medical Journal. 121: 516-521.
Cetin M, Cakici M, Zencir C, et al. 2014. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 15; :950-6.
Cheng K, Rehman SM, Taggart DP. 2015. A Review of Differing Techniques of Mammary Artery Harvesting on Sternal Perfusion: Time for a Randomized Study? Ann. Thorac. Surg. 100: 1942-53.
Cohn LH. 2001. Use of Internal Mammary Artery graft and in-hospital mortality and other adverse outcomes associated with coronary artery bypass surgery. Circulation. 103: 483–4.
Davignon J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 109: 39-43.
Duncan RF, Dundon BK, Nelson AJ, et al. 2011. A study of the 16-Segment Regional Wall Motion Scoring Index and biplane Simpson's rule for the calculation of left ventricular ejection fraction: a comparison with cardiac magnetic resonance imaging. Echocardiography 28: 597-604.
Grover-Páez F, Zavalza-Gómez AB. 2009. Endothelial dysfunction and cardiovascular risk
factors. Diabetes Res Clin Pract. 84: 1-10.
Grundy SM, Cleeman JI, Merz CN, et al. 2004. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-39.
Haberal I, Gurer O, Ozsoy D, Erturk E. 2015. Coronary flow reserve in patients with left anterior descending artery-left internal mammary artery long patch plasty anastomosis: a prospective study. J Cardiothorac Surg. 10: 51.
Harskamp RE, Alexander JH, Ferguson TB, Hager R, Mack MJ, Englum B. 2016. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the PREVENT IV Trial. Circulation. 12; 131- 138.
Hata M, Shiono M, Orime Y, et al. 2000. Clinical results of coronary artery by pass grafting with use of internal thoracic artery under low free flow conditions.J.Thorac Cardiovas Surg 119: 125-9.
He GW, Fan L, Grove KL, Funnary A, et al. 2011. Expression and function of endothelial nitric oxide synthase messenger RNA and protein are higher in internal mammary than in radial arteries. Ann Thorac Surg. 92; 845-850.
Honda K, Okamura Y, Nishimura Y, et al. 2015. Graft flow assessment using a transit time flow meter in fractional flow reserve-guided coronary artery bypass surgery. J Thorac Cardiovasc Surg. 149: 1622–8.
Karthik S, Srinivasan AK, Grayson AD, Jackson M, Mediratta NK. 2004. Left Internal Mammary Artery to the Left Anterior Descending Artery: effect on morbidity and mortality and reasons for nonusage. Ann Thorac Surg. 78: 142–8.
Kolh P, Wijns W, Danchin N, et al. 2010. Guidelines on myocardial revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 38(Suppl): S1–S52.
Lambert J, Aarsen M, Donker AJ, Stehouwer CD. 1996. Endothelium-dependent and-independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 16: 705-11.
Leavitt BJ, Olmstead EM, Plume SK, et al. 1997. Use of the Internal Mammary Artery Graft in Northern New England. Circulation. 96 (Suppl II): 32–7.
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2019. 2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 40: 87–165.
Oesterle A, Laufs U, Liao JK. 2017. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 120: 229-243.
Otsuka F, Yahagi K, Sakakura K, Virmani R. 2013. Why is the mammary artery so special and What protect it from atherosclerosis? Ann Cardiothorac Surg. 2: 519-526.
Perk J, De Backer G, Gohlke H, et al. 2012. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 33; 1635-701.
Tasolar H, Cetin M, Balli M, et al. 2016. CHA2DS2-Vasc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol. 16: 742-8.
Van Guilder GP, Hoetzer GL, Dengel DR, Stauffer BL, DeSouza CA. 2006. Impaired endothelium- dependent vasodilation in normotensive and normoglycemic obese adult humans. J Cardiovasc Pharmacol. 47: 310-3.
Williams B, Mancia G, Spiering W, et al. 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 33: 3021–3104.
Wojszel ZB, Kasiukiewicz A, Swietek M, Swietek ML, Magnuszewski L. 2019. CHA2DS2-VASc score can guide the screening of atrial fibrillation - cross-sectional study in a geriatric ward. Clinical Interventions in Aging. 14: 879–887.
Zhao SG, Xu JJ, Tao ZH, et al. 2019. CHA2DS2-Vasc score and CHA2DS2-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents. Journal of International Medical Research. 47; 2533–2544.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).